AVROBIO shares are trading higher after the company announced data from the Phase 1/2 clinical trial of an investigational gene therapy for cystinosis.
Portfolio Pulse from Benzinga Newsdesk
AVROBIO announced positive data from the Phase 1/2 clinical trial of its investigational gene therapy for cystinosis, leading to a rise in its share price.
May 18, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AVROBIO shares are trading higher after the company announced positive data from the Phase 1/2 clinical trial of its investigational gene therapy for cystinosis.
The positive data from the Phase 1/2 clinical trial of AVROBIO's investigational gene therapy for cystinosis indicates potential success in further development and commercialization. This news is likely to boost investor confidence in the company, leading to a short-term increase in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100